Your browser doesn't support javascript.
loading
No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity.
Barnett, Gillian C; Kerns, Sarah L; Dorling, Leila; Fachal, Laura; Aguado-Barrera, Miguel E; Martínez-Calvo, Laura; Jandu, Harkeran K; Welsh, Ceilidh; Tyrer, Jonathan; Coles, Charlotte E; Haviland, Joanne S; Parker, Christopher; Gómez-Caamaño, Antonio; Calvo-Crespo, Patricia; Sosa-Fajardo, Paloma; Burnet, Neil G; Summersgill, Holly; Webb, Adam; De Ruysscher, Dirk; Seibold, Petra; Chang-Claude, Jenny; Talbot, Christopher J; Rattay, Tim; Parliament, Matthew; De Ruyck, Kim; Rosenstein, Barry S; Pharoah, Paul D P; Dunning, Alison M; Vega, Ana; West, Catharine M L.
Afiliação
  • Barnett GC; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, United Kingdom. Electronic address: gill.barnett@addenbrookes.nhs.uk.
  • Kerns SL; Department of Radiation Oncology, University of Rochester Medical Center, Rochester, New York.
  • Dorling L; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
  • Fachal L; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom.
  • Aguado-Barrera ME; Fundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Santiago de Compostela, A Coruña, Spain; Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain.
  • Martínez-Calvo L; Fundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Santiago de Compostela, A Coruña, Spain; Grupo Genética en Cáncer y Enfermedades Raras, Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, A Coruña, Spain.
  • Jandu HK; Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.
  • Welsh C; Department of Oncology, University of Cambridge, Cambridge, United Kingdom.
  • Tyrer J; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
  • Coles CE; Department of Oncology, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, United Kingdom.
  • Haviland JS; Clinical Trials and Statistics Unit, Institute of Cancer Research, London, United Kingdom.
  • Parker C; Institute of Cancer Research & Royal Marsden NHS Foundation Trust, London, United Kingdom.
  • Gómez-Caamaño A; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain.
  • Calvo-Crespo P; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain.
  • Sosa-Fajardo P; Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela, Spain.
  • Burnet NG; Proton Beam Therapy Centre, Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Summersgill H; Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom.
  • Webb A; Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.
  • De Ruysscher D; Department of Radiation Oncology (Maastro Clinic), Maastricht University Medical Center, GROW School for Oncology and Developmental Biology, Maastricht, The Netherlands; Radiation Oncology, Katholieke Universiteit Leuven, Leuven, Belgium.
  • Seibold P; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Chang-Claude J; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany.
  • Talbot CJ; Department of Genetics and Genome Biology, University of Leicester, Leicester, United Kingdom.
  • Rattay T; Leicester Cancer Research Centre, University of Leicester, Leicester, United Kingdom.
  • Parliament M; Division of Radiation Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada.
  • De Ruyck K; Departments of Basic Medical Sciences and Radiotherapy, Ghent University Hospital, Ghent, Belgium.
  • Rosenstein BS; Departments of Radiation Oncology and Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York.
  • Pharoah PDP; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
  • Dunning AM; Centre for Cancer Genetic Epidemiology, University of Cambridge, Strangeways Research Laboratory, Cambridge, United Kingdom.
  • Vega A; Wellcome Sanger Institute, Wellcome Genome Campus, Hinxton, United Kingdom; Fundación Pública Galega de Medicina Xenómica (FPGMX)-SERGAS, Santiago de Compostela, A Coruña, Spain; Biomedical Network on Rare Diseases (CIBERER), Spain.
  • West CML; Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie NHS Foundation Trust, Manchester, United Kingdom.
Int J Radiat Oncol Biol Phys ; 114(3): 494-501, 2022 11 01.
Article em En | MEDLINE | ID: mdl-35840111
ABSTRACT

PURPOSE:

Our aim was to test whether updated polygenic risk scores (PRS) for susceptibility to cancer affect risk of radiation therapy toxicity. METHODS AND MATERIALS Analyses included 9,717 patients with breast (n=3,078), prostate (n=5,748) or lung (n=891) cancer from Radiogenomics and REQUITE Consortia cohorts. Patients underwent potentially curative radiation therapy and were assessed prospectively for toxicity. Germline genotyping involved genome-wide single nucleotide polymorphism (SNP) arrays with nontyped SNPs imputed. PRS for each cancer were generated by summing literature-identified cancer susceptibility risk alleles 352 breast, 136 prostate, and 24 lung. Weighted PRS were generated using log odds ratio (ORs) for cancer susceptibility. Standardized total average toxicity (STAT) scores at 2 and 5 years (breast, prostate) or 6 to 12 months (lung) quantified toxicity. Primary analysis tested late STAT, secondary analyses investigated acute STAT, and individual endpoints and SNPs using multivariable regression.

RESULTS:

Increasing PRS did not increase risk of late toxicity in patients with breast (OR, 1.000; 95% confidence interval [CI], 0.997-1.002), prostate (OR, 0.99; 95% CI, 0.98-1.00; weighted PRS OR, 0.93; 95% CI, 0.83-1.03), or lung (OR, 0.93; 95% CI, 0.87-1.00; weighted PRS OR, 0.68; 95% CI, 0.45-1.03) cancer. Similar results were seen for acute toxicity. Secondary analyses identified rs138944387 associated with breast pain (OR, 3.05; 95% CI, 1.86-5.01; P = 1.09 × 10-5) and rs17513613 with breast edema (OR, 0.94; 95% CI, 0.92-0.97; P = 1.08 × 10-5).

CONCLUSIONS:

Patients with increased polygenic predisposition to breast, prostate, or lung cancer can safely undergo radiation therapy with no anticipated excess toxicity risk. Some individual SNPs increase the likelihood of a specific toxicity endpoint, warranting validation in independent cohorts and functional studies to elucidate biologic mechanisms.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Produtos Biológicos / Neoplasias da Mama Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Próstata / Lesões por Radiação / Produtos Biológicos / Neoplasias da Mama Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans / Male Idioma: En Revista: Int J Radiat Oncol Biol Phys Ano de publicação: 2022 Tipo de documento: Article